AT220153B - Process for the preparation of new iminodibenzyl derivatives and their salts - Google Patents
Process for the preparation of new iminodibenzyl derivatives and their saltsInfo
- Publication number
- AT220153B AT220153B AT152061A AT152061A AT220153B AT 220153 B AT220153 B AT 220153B AT 152061 A AT152061 A AT 152061A AT 152061 A AT152061 A AT 152061A AT 220153 B AT220153 B AT 220153B
- Authority
- AT
- Austria
- Prior art keywords
- general formula
- salts
- compound
- acid
- group
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 7
- ZSMRRZONCYIFNB-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[b][1]benzazepine Chemical class C1CC2=CC=CC=C2NC2=CC=CC=C12 ZSMRRZONCYIFNB-UHFFFAOYSA-N 0.000 title claims description 5
- 238000000034 method Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical group [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- 125000005277 alkyl imino group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 239000008139 complexing agent Substances 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- -1 alkylene radical Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001519 thymoleptic effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Description
<Desc/Clms Page number 1>
Verfahren zur Herstellung von neuen Iminodibenzylderivaten und deren Salzen
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung neuer N-heterocyclischer Verbindungen mit wertvollen pharmakologischen Eigenschaften sowie der zugehörigen Zwischenprodukte.
Es wurde gefunden, dass man Verbindungen mit wertvollen pharmakologischen Eigenschaften, die der allgemeinen Formel I entsprechen,
EMI1.1
worin X einen geradkettigen oder verzweigten Alkylenrest mit 2-6 Kohlenstoffatomen und Am eine Dialkylaminogruppe bedeutet, wobei einer der beiden Alkylreste einer Dialkylaminogruppe Am direkt (1) mit dem Alkylenrest X oder beide Alkylreste unter sich direkt (2) oder über ein Sauerstoffatom (3), eine niedere Alkylimino- (4), Hydroxyalkylimino- (5) oder Alkanoyloxyalkyliminogruppe (6) verbunden sein können, bzw.
deren Salze mit anorganischen oder organischen Säuren herstellen kann, indem man eine Verbindung der allgemeinen Formel II
EMI1.2
worin X und Am die oben angegebene Bedeutung haben, mit Sauerstoff oder Wasserstoffperoxyd in einer neutralen bis schwach sauren wässerigen Lösung in Gegenwart einer Verbindung mit der Atomgruppierung - CO-C (OH) = C (OH)- oder-CO-CO-CO-, wie z. B. Ascorbinsäure oder Dehydroascorbinsäure, von Ionen eines Schwermetalles der Gruppe Eisen, Nickel, Kobalt und Mangan und gegebenenfalls eines Komplexbildners, z. B. Äthylendiamin-tetraessigsäure, Zitronensäure oder o-Phenanthrolin, oxydiert.
Die folgenden Formeln sind spezielle Beispiele zur Erläuterung der obenerwähnten sechs Bindungsmöglichkeiten in der Gruppierung X-Am :
EMI1.3
<Desc/Clms Page number 2>
EMI2.1
EMI2.2
2-Propylen-, 1, 3-zinyl-(1)-oder 4-Hydroxyäthyl-piperazinyl-(1)-rest und X-Am zusammen ferner z. B. durch den 1- Methyl-piperidyl- (3)-methyl, l-Methyl-piperidyl- (2)-äthyl- oder 1-Methyl-pyrrolidyl-(2)-äthylrest verkörpert.
Ausgangsstoffe der allgemeinen Formel II werden erhalten, indem man Iminodibenzyl in Gegenwart eines alkalischen Kondensationsmittels mit einem reaktionsfähigen Ester eines Alkohols der allgemeinen Formel
HO-X-Am', (III) worin Am'einen Rest entsprechend der Definition für Am mit Ausnahme einer Monoalkylaminogruppe oder eine niedere N-Arylmethy1alky1aminogruppe oder N-Acyl-alkylaminogruppe bedeutet und X die oben angegebene Bedeutung hat, umsetzt. Nötigenfalls wandelt man hierauf das Kondensationsprodukt der allgemeinen Formel IV, die einen Teil der Verbindungen der allgemeinen Formel II bereits mitumfasst :
EMI2.3
je nach der Bedeutung von Am', durch vorzugsweise saure Hydrolyse oder durch Hydrogenolyse in eine Verbindung der oben definierten allgemeinen Formel I um, worin Am durch eine niedere Alkylaminogruppe verkörpert ist.
Als alkalische Kondensationsmittel für die Umsetzung von Iminodibenzyl mit reaktionsfähigen Estern von basischen Alkoholen der allgemeinen Formel III eignen sich insbesondere Natriumamid, Lithiumamid, Kaliumamid, Natrium, Kalium, Butyllithium, Phenyllithium, Natriumhydrid oder Lithiumhydrid. Die Umsetzung kann in An- oder Abwesenheit eines inerten organischen Lösungsmittels, wovon als Beispiel Benzol, Toluol und Xylole genannt seien, durchgeführt werden.
Nach einem weiteren Verfahren erhält man Verbindungen der allgemeinen Formel 11, indem man ein Halogenid einer Verbindung der allgemeinen Formel
EMI2.4
worin X die oben angegebene Bedeutung hat, mit einer Verbindung der allgemeinen Formel
Am"-H, (VI)
<Desc/Clms Page number 3>
worin Am" die oben angegebene Bedeutung hat, jedoch naturgemäss keine Bindung zwischen einem Alkylrest von Am" und X vorliegen kann, in Gegenwart eines säurebindenden Mittels, vorzugsweise eines Überschusses an umzusetzendem Amin der allgemeinen Formel VI umsetzt.
Die erfindungsgemäss herstellbaren Verbindungen besitzen insbesondere antiallergische, sedative, serotoninantagonistische, antipyretische und thymoleptische Wirksamkeit bei nur geringen vegetativen Nebenwirkungen. Sie eignen sich beispielsweise zur Behandlung von gewissen Formen von Geisteskrankheiten, insbesondere Gemütsdepressionen, wobei sie peroral oder in Form von wässerigen Lösungen nichttoxischer Salze auch parenteral angewendet werden können. Teilweise eignen sie sich auch als Zwischenprodukte für die Herstellung weiterer Stoffe mit ähnlichen Eigenschaften.
Mit anorganischen oder organischen Säuren, wie Salzsäure, Bromwasserstoffsäure, Schwefelsäure, Phosphorsäure, Methansulfonsäure, Äthandisulfonsäure, Essigsäure, Bernsteinsäure, Fumarsäure, Maleinsäure, Äpfelsäure, Weinsäure, Citronensäure, Benzoesäure und Phthalsäure, bilden die erfindungsgemäss herstellbaren Verbindungen der allgemeinen Formel I Salze, welche zum Teil wasserlöslich sind.
Das nachfolgende Beispiel soll die erfindungsgemässe Herstellung von Verbindungen der allgemeinen Formel I näher erläutern, stellt jedoch keineswegs die einzige Ausführungsmöglichkeit derselben dar.
Im Beispiel bedeuten Teile, sofern nichts anderes vermerkt ist, Gewichtsteile ; diese verhalten sich zu Volumteilen wie g zu cm3. Die Temperaturen sind in Celsiusgraden angegeben.
Beispiel : 10, 5 Teile Ferrosulfat, 76, 2 Teile Dinatriumsalz der Äthylendiamintetraessigsäure, 75 Teile Ascorbinsäure und schliesslich unter starkem Rühren 75 Teile 5- (y-Dimethylaminopropyl) -iminodibenzyl werden
EMI3.1
Hierauf wird die Lösung abgekühlt, mit konzentriertem Ammoniak auf pH 10 eingestellt und die nun tiefblau gefärbte Lösung dreimal mit Äthylacetat ausgeschüttelt. Die vereinigten Auszüge werden mindestens sechsmal mit Wasser gewaschen, um allfällige gelöste Eisensalze zu entfernen. Hierauf schüttelt man die klare Äthylacetatlösung dreimal mit 50 Volumteilen 2-n. Salzsäure aus, stellt die klaren sauren Extrakte mit konzentriertem Ammoniak alkalisch und nimmt die ausgeschiedenen basischen Stoffe wiederum in Äthylacetat auf. Die Äthylacetatlösung wird über Natriumsulfat getrocknet und durch Eindampfen im Vakuum vom Lösungsmittel befreit, wobei ein fast schwarzes Öl hinterbleibt.
Dieses wird in 420 Volumteilen 70%igem Methanol gelöst und die Lösung viermal mit je 420 Volumteilen Pentan ausgeschüttelt, wobei sich an den Wänden des Scheidetrichters ein schwarzes Harz absetzt, das vernachlässigt werden kann. Hierauf wird die methanolische Lösung im Vakuum eingeengt, der Rückstand in Äthylacetat aufgenommen, die Lösung mit Wasser gewaschen, über Natriumsulfat getrocknet und im Vakuum eingedampft. Der Rückstand wird an einer in Äther bereiteten Säure aus 450 Teilen Silicagel chromatographiert. Beim Eluieren mit Gemischen von gleichen Teilen Äther und Aceton werden Fraktionen des Rohproduktes mit zwischen 120 und 1260 liegenden Schmelztemperaturbereichen eluiert.
Diese werden vereinigt und zunächst aus sehr wenig Aceton und anschliessend aus viel Äther umkristallisiert, wobei man das 2- Hydroxy-5- (y-dimethylamino-propyl) -iminodibenzyl vom Smp. 134-1350 erhält. Weitere Reinsubstanz kann aus nachfolgenden Äther-Aceton-Eluaten und Aceton-Eluaten, deren Rückstand einen Schmelzpunktbereich von 100 bis 1140 aufweist, durch mehrmalige analoge Umkristallisation gewonnen werden.
<Desc / Clms Page number 1>
Process for the preparation of new iminodibenzyl derivatives and their salts
The present invention relates to a process for the preparation of new N-heterocyclic compounds with valuable pharmacological properties and the associated intermediates.
It has been found that compounds with valuable pharmacological properties which correspond to the general formula I
EMI1.1
wherein X is a straight-chain or branched alkylene radical with 2-6 carbon atoms and Am is a dialkylamino group, where one of the two alkyl radicals of a dialkylamino group Am is directly (1) with the alkylene radical X or both alkyl radicals directly (2) or via an oxygen atom (3) , a lower alkylimino (4), hydroxyalkylimino (5) or alkanoyloxyalkylimino group (6) can be linked, or
their salts can be prepared with inorganic or organic acids by adding a compound of the general formula II
EMI1.2
where X and Am have the meaning given above, with oxygen or hydrogen peroxide in a neutral to weakly acidic aqueous solution in the presence of a compound with the atomic grouping - CO-C (OH) = C (OH) - or-CO-CO-CO- such as B. ascorbic acid or dehydroascorbic acid, ions of a heavy metal from the group iron, nickel, cobalt and manganese and optionally a complexing agent, e.g. B. ethylenediamine tetraacetic acid, citric acid or o-phenanthroline, oxidized.
The following formulas are specific examples to illustrate the above-mentioned six bonding possibilities in the grouping X-Am:
EMI1.3
<Desc / Clms Page number 2>
EMI2.1
EMI2.2
2-propylene, 1, 3-zinyl (1) or 4-hydroxyethyl-piperazinyl (1) radical and X-Am together also z. B. embodied by 1-methyl-piperidyl- (3) -methyl, l-methyl-piperidyl- (2) -ethyl- or 1-methyl-pyrrolidyl- (2) -ethyl radical.
Starting materials of the general formula II are obtained by reacting iminodibenzyl in the presence of an alkaline condensing agent with a reactive ester of an alcohol of the general formula
HO-X-Am ', (III) where Am' denotes a radical corresponding to the definition for Am with the exception of a monoalkylamino group or a lower N-arylmethy1alky1amino group or N-acyl-alkylamino group and X has the meaning given above. If necessary, the condensation product of the general formula IV is then converted, which already includes some of the compounds of the general formula II:
EMI2.3
depending on the meaning of Am ', by preferably acid hydrolysis or by hydrogenolysis into a compound of the general formula I defined above, in which Am is represented by a lower alkylamino group.
Sodium amide, lithium amide, potassium amide, sodium, potassium, butyllithium, phenyllithium, sodium hydride or lithium hydride are particularly suitable as alkaline condensing agents for the reaction of iminodibenzyl with reactive esters of basic alcohols of the general formula III. The reaction can be carried out in the presence or absence of an inert organic solvent, examples of which are benzene, toluene and xylenes.
According to a further process, compounds of the general formula 11 are obtained by adding a halide of a compound of the general formula
EMI2.4
wherein X has the meaning given above, with a compound of the general formula
Am "-H, (VI)
<Desc / Clms Page number 3>
in which Am "has the meaning given above, but of course there can be no bond between an alkyl radical of Am" and X, in the presence of an acid-binding agent, preferably an excess of amine of the general formula VI to be converted.
The compounds which can be prepared according to the invention have, in particular, antiallergic, sedative, serotonin-antagonistic, antipyretic and thymoleptic activity with only minor vegetative side effects. They are suitable, for example, for the treatment of certain forms of mental illness, in particular mood depression, and they can also be used orally or parenterally in the form of aqueous solutions of non-toxic salts. Some of them are also suitable as intermediate products for the manufacture of other substances with similar properties.
With inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, ethane disulphonic acid, acetic acid, succinic acid, fumaric acid, maleic acid, malic acid, tartaric acid, citric acid, benzoic acid and phthalic acid, the compounds of the general formula I which can be prepared according to the invention form salts, which for the Partly are water soluble.
The following example is intended to explain the preparation according to the invention of compounds of the general formula I in more detail, but in no way represents the only possible way of carrying out the same.
In the example, parts mean parts by weight, unless otherwise noted; these are related to parts of volume as g to cm3. The temperatures are given in degrees Celsius.
Example: 10.5 parts of ferrous sulfate, 76.2 parts of the disodium salt of ethylenediaminetetraacetic acid, 75 parts of ascorbic acid and finally 75 parts of 5- (γ-dimethylaminopropyl) -iminodibenzyl with vigorous stirring
EMI3.1
The solution is then cooled, adjusted to pH 10 with concentrated ammonia and the solution, which is now deep blue, is extracted three times with ethyl acetate. The combined extracts are washed at least six times with water in order to remove any dissolved iron salts. The clear ethyl acetate solution is then shaken three times with 50 parts by volume of 2-n. Hydrochloric acid, makes the clear acidic extracts alkaline with concentrated ammonia and takes up the precipitated basic substances in ethyl acetate. The ethyl acetate solution is dried over sodium sulfate and freed from the solvent by evaporation in vacuo, an almost black oil remaining behind.
This is dissolved in 420 parts by volume of 70% methanol and the solution is shaken out four times with 420 parts by volume of pentane each time, a black resin which can be neglected settles on the walls of the separating funnel. The methanolic solution is then concentrated in vacuo, the residue is taken up in ethyl acetate, the solution is washed with water, dried over sodium sulfate and evaporated in vacuo. The residue is chromatographed on an acid prepared in ether from 450 parts of silica gel. When eluting with mixtures of equal parts of ether and acetone, fractions of the crude product with melting temperature ranges between 120 and 1260 are eluted.
These are combined and recrystallized first from very little acetone and then from a lot of ether, 2-hydroxy-5- (γ-dimethylamino-propyl) -iminodibenzyl having a melting point of 134-1350. Further pure substance can be obtained from the following ether-acetone eluates and acetone eluates, the residue of which has a melting point range of 100 to 1140, by repeated analogous recrystallization.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT152061A AT220153B (en) | 1960-05-27 | 1960-05-27 | Process for the preparation of new iminodibenzyl derivatives and their salts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT152061A AT220153B (en) | 1960-05-27 | 1960-05-27 | Process for the preparation of new iminodibenzyl derivatives and their salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT220153B true AT220153B (en) | 1962-03-12 |
Family
ID=29588149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT152061A AT220153B (en) | 1960-05-27 | 1960-05-27 | Process for the preparation of new iminodibenzyl derivatives and their salts |
Country Status (1)
| Country | Link |
|---|---|
| AT (1) | AT220153B (en) |
-
1960
- 1960-05-27 AT AT152061A patent/AT220153B/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19724186C2 (en) | Process for the mono- and 1,7-bis-N-ß-hydroxyalkylation of cycles and the corresponding N-ß-hydroxyalkyl-1,4,7,10-tetraazacyclododecane-Li salt complexes | |
| AT220153B (en) | Process for the preparation of new iminodibenzyl derivatives and their salts | |
| EP0061418A1 (en) | 7-Alpha-alkoxycarbonyl-15-beta-16-beta-methylene-4 androstene, process for their preparation and their utilization as pharmaceutical preparations | |
| CH628646A5 (en) | METHOD FOR PRODUCING 3 BETA, 25-DIHYDROXYCHOLESTA-5,22-DIEN-7-ON DERIVATIVES. | |
| AT349481B (en) | METHOD FOR PRODUCING NEW MORPHOLINE DERIVATIVES, THEIR N-OXIDES AND SALTS | |
| AT369733B (en) | METHOD FOR PRODUCING NEW 1,4-DIPHENYLPYRAZOLE DERIVATIVES | |
| AT369732B (en) | METHOD FOR PRODUCING NEW 1,4-DIPHENYLPYRAZOLE DERIVATIVES | |
| AT230895B (en) | Process for the preparation of new 6, 11-dihydrodibenzo- [b, e] -thiazepine- [1, 4] derivatives | |
| AT256851B (en) | Process for the preparation of new benzodiazepine derivatives | |
| AT206444B (en) | Process for the preparation of new pyridazine derivatives | |
| CH376509A (en) | Process for the preparation of new N-heterocyclic compounds | |
| AT337173B (en) | PROCESS FOR THE PRODUCTION OF NEW ISOINDOLINE DERIVATIVES AND THEIR SALT | |
| AT269149B (en) | Process for the preparation of new basic substituted oximes of 6,11-dihydro-dibenz- [b, e] -oxepin- or -thiepin-11-ones and their salts | |
| AT358747B (en) | METHOD FOR THE PRODUCTION OF NEW D-HOMOSTEROIDS | |
| AT218526B (en) | Process for the production of new phenthiazine derivatives | |
| AT256874B (en) | Process for the production of new heterocyclic guanidine compounds or their acid addition salts | |
| AT242116B (en) | Process for the preparation of new 6-acylthio-8-halogenoctanoic acids and their derivatives | |
| AT233179B (en) | Process for the preparation of the new 3β-hydroxy- and 3β-acyloxy-6, 16-dimethylpregna-5, 16-dien-20-one | |
| AT262271B (en) | Process for the preparation of new 9,10-dihydro-4H-benzo [4,5] cyclohepta [1,2-b] thiophene derivatives and their salts | |
| DE952900C (en) | Process for the preparation of 5-alkoxy-6-formyl-7-oxychromones | |
| AT349025B (en) | PROCESS FOR THE PREPARATION OF NEW NAPHTHYRIDE DERIVATIVES AND OF THEIR ACID ADDITION SALTS | |
| AT247869B (en) | Process for the production of new 4-oxo-1, 2, 3, 4-tetrahydro-quinazolines, their acid addition salts and quaternary ammonium compounds | |
| AT216156B (en) | Process for the preparation of polyhydrophenanthrene compounds | |
| AT266140B (en) | Process for the preparation of new pyrazine compounds | |
| AT247339B (en) | Process for the production of new quinazolone compounds |